DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

Autor: Qing Zhu, Janess M. Mendoza, Sarah T. C. Elliott, David B. Weiner, Ami Patel, Trevor R.F. Smith, Leslie Wachter-Rosati, Jian Yan, Megan C. Wise, Seleeke Flingai, Nicole L. Kallewaard, Karuppiah Muthumani, Daniel H. Park, Ebony Benjamin, Kate E. Broderick, Josephine M. McAuliffe, Niranjan Y. Sardesai, Laurent Humeau, Stephanie Ramos, Katherine Schultheis
Rok vydání: 2017
Předmět:
Zdroj: npj Vaccines
npj Vaccines, Vol 2, Iss 1, Pp 1-9 (2017)
NPJ Vaccines
ISSN: 2059-0105
DOI: 10.1038/s41541-017-0020-x
Popis: Influenza virus remains a significant public health threat despite innovative vaccines and antiviral drugs. A major limitation to current vaccinations and therapies against influenza virus is pathogenic diversity generated by shift and drift. A simple, cost-effective passive immunization strategy via in vivo production of cross-protective antibody molecules may augment existing vaccines and antiviral drugs in seasonal and pandemic outbreaks. We engineered synthetic plasmid DNA to encode two novel and broadly cross-protective monoclonal antibodies targeting influenza A and B. We utilized enhanced in vivo delivery of these plasmid DNA-encoded monoclonal antibody (DMAb) constructs and show that this strategy induces robust levels of functional antibodies directed against influenza A and B viruses in mouse sera. Mice receiving a single inoculation with anti-influenza A DMAb survive lethal Group 1 H1 and Group 2 H3 influenza A challenges, while inoculation with anti-influenza B DMAb yields protection against lethal Victoria and Yamagata lineage influenza B morbidity and mortality. Furthermore, these two DMAbs can be delivered coordinately resulting in exceptionally broad protection against both influenza A and B. We demonstrate this protection is similar to that achieved by conventional protein antibody delivery. DMAbs warrant further investigation as a novel immune therapy platform with distinct advantages for sustained immunoprophylaxis against influenza.
Nucleic acid delivery: Instant, wide-ranging protection against influenza A and B A novel innoculation technique involving the injection of antibody-producing plasmid DNA has shown to be effective against influenza in mice. The flu is responsible for up to half a million deaths each year and up to five million cases of severe disease, while also posing a substantial pandemic threat, even with our current repertoire of vaccines. A team of researchers led by Sarah Elliott and David Weiner of The Wistar Institute of Anatomy and Biology, Philadelphia, developed potent plasmid-based constructs that, once injected, entered hosts’ cells and utilized cellular machinery to encode antibodies protective against a range of influenza A and B subtypes. DNA inoculation conferred acute protection from disease, with treated individuals also being immune to subsequent exposure. This approach warrants further investigation as an alternative technology for practical delivery of monoclonal antibody therapeutics.
Databáze: OpenAIRE
Externí odkaz: